This inventor holds 3 USPTO granted patents and 10 published patent applications and 5 EPO patents. Top assignee: Promedior, Inc.. Active years: 2012-2017.
Company Filing History:
Years Active: 2012-2017
Title: W Scott Willett: Innovator in Therapeutic Peptides
Introduction
W Scott Willett is a notable inventor based in Doylestown, PA, with a focus on advancements in therapeutic polypeptides. With a total of three patents to his name, Willett is pushing the boundaries of pharmaceutical compositions to improve patient outcomes in the medical field.
Latest Patents
Willett's latest contributions include groundbreaking patents centered around SAP (Serum Amyloid P) variants and their utilization. His innovations address the critical issue of polypeptide stability in the body, as these compounds are often susceptible to denaturation and enzymatic degradation, particularly in blood, liver, and kidney environments. One patent emphasizes innovative SAP variant proteins and pharmaceutical compositions that boast an extended in vivo half-life and prolonged shelf-life, leading to enhanced stability compared to traditional human SAP. This advancement reduces the frequency of dosing, ultimately benefiting patients.
Another significant patent by Willett involves discovering that modifications to the glycan structure of human SAP polypeptides can markedly enhance their biological activity. This invention provides methods for the addition, deletion, or alteration of sugar residues to create SAP polypeptides with a targeted glycosylation pattern, contributing to improved efficacy in therapeutic applications.
Career Highlights
W Scott Willett's career is characterized by his commitment to addressing the challenges faced in administering polypeptide drugs. As part of Promedior, Inc., he has played a pivotal role in the development of new peptide formulations that aim to provide sustained therapeutic effects while ensuring safety and stability over time. His influential work has significantly impacted the pharmaceutical industry, offering promising solutions for complex medical conditions.
Collaborations
Willett collaborates closely with his coworker Richard J Caimi, who shares a dedication to pioneering advancements in therapeutic treatments. Together, they have embarked on various projects aimed at enhancing the clinical applications of SAP derivatives.
Conclusion
W Scott Willett stands out as an innovative force in the realm of therapeutic peptides. Through his patents, he addresses crucial issues related to polypeptide stability and efficacy, making significant strides in improving pharmaceutical compositions. His work at Promedior, Inc., along with his collaboration with Richard J Caimi, showcases a commitment to advancing medical science for better patient care.